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Identification of prognostic genes 
and gene sets for early-stage non-
small cell lung cancer using bi-level 
selection methods
Suyan Tian1,2, Chi Wang3, Howard H. Chang4 & Jianguo Sun1,5
In contrast to feature selection and gene set analysis, bi-level selection is a process of selecting not 
only important gene sets but also important genes within those gene sets. Depending on the order 
of selections, a bi-level selection method can be classified into three categories – forward selection, 
which first selects relevant gene sets followed by the selection of relevant individual genes; backward 
selection which takes the reversed order; and simultaneous selection, which performs the two tasks 
simultaneously usually with the aids of a penalized regression model. To test the existence of subtype-
specific prognostic genes for non-small cell lung cancer (NSCLC), we had previously proposed the 
Cox-filter method that examines the association between patients’ survival time after diagnosis with 
one specific gene, the disease subtypes, and their interaction terms. In this study, we further extend 
it to carry out forward and backward bi-level selection . Using simulations and a NSCLC application, 
we demonstrate that the forward selection outperforms the backward selection and other relevant 
algorithms in our setting. Both proposed methods are readily understandable and interpretable. 
Therefore, they represent useful tools for the researchers who are interested in exploring the prognostic 
value of gene expression data for specific subtypes or stages of a disease.
Feature selection, where the primary objective is selection of individual relevant variables, such as genes associ-
ated with a phenotype of interest, is an important topic in the field of bioinformatics. Because gene expression 
profiles exhibit grouped structure with genes inside each group being highly correlated to each other, gene set 
analysis has become popular and widespread over the last decade1,2. The goal of a gene set analysis method is to 
examine the association of a gene set with the phenotype of interest, meaning the selection of relevant gene sets. 
Both gene and gene set selections lead to more parsimonious final models with better predictive performance and 
more meaningful biological interpretation.
In contrast to feature selection and gene set analysis, bi-level selection is a process of selecting relevant features 
at two levels, as its name implies3. Bi-level selection is motivated by the fact that some genes within a gene set may 
be unrelated to the phenotype of interest, although the gene set as a whole is involved in the biological process. 
Since a bi-level selection analysis is interested in selecting not only important groups/gene sets but also those 
important members/genes inside those groups/gene sets, a feature may be thus referred to as either a gene set or 
a gene here.
Based on the order of selection on genes and gene sets, bi-level selection methods can be classified into three 
categories: (1) the forward selection method which first selects relevant gene sets followed by the selection of 
relevant individual genes, e.g.,4; (2) the backward selection method such as5–7 which takes the reversed order; 
and (3) the simultaneous selection method which selects important gene sets and genes at the same time, usually 
by the means of adding a penalty term which penalizes all genes inside the same group similarly, e.g.,3,8. The 
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simultaneous selection method using a penalized regression model is more statistically sophisticated, compared 
to the first two methods. Here we focus on the forward and backward selection methods due to their ease in 
implementation and thus wide utilization.
Even though both the forward and backward selection methods can implement two level selections, their 
relative emphases on these two levels may differ. Nevertheless, their common drawback is that the small number 
of selected features in the first step may lead to challenges in performing the second step. Intuitively, the forward 
method is superior to the backward method because the extraction of core genes before the identification of 
important gene sets may screen out the gene sets whose members have subtle individual effects but their coordi-
nated effects being significant when taken together.
Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths in many countries9. Adenocarcinoma 
(AC) and squamous cell carcinoma (SCC) are two major histological subtypes of NSCLC. There is increasing evi-
dence to support that AC and SCC differ in the composition of genes and molecular characteristics10. Therefore, 
they should be regarded as two distinct diseases and treated with different treatment strategies.
Currently, treatment choices for these two subtypes are very homogeneous, mainly depending on the stage at 
which the cancer is diagnosed. It is becoming critical to evaluate the risk profiles of patients using a reliable gene/
gene set signature. Given the fundamental differences between AC and SCC, the genes/gene sets associated with 
recurrence and survival rates for each histology subtype are expected to be different11–13. To test the existence of 
subtype-specific prognostic genes, two statistical methods were proposed previously by us11,12. For example, the 
so-called Cox-filter model11 fits a Cox model using gene, subtype, and their interaction term as covariates for each 
gene. After filtering and excluding insignificant genes, the Cox-filter model identifies subtype-specific prognostic 
genes (discussed in detail in the Methods section). However, the Cox-filter method does not take the grouping 
structures among genes into account, and thus selects genes based on the strength of their individual effects and 
introduces false positives.
In this study, we extend the Cox-filter model to two bi-level selection methods — one forward method and one 
backward method — by constructing patients’ risk profiles at the gene set level using the sign average method6,14. 
The two Cox-filter extensions are then applied to NSCLC data to investigate if they can alleviate the limitations of 
the original Cox-filter model.
Results
Simulated Data. To examine the characteristics of our proposed procedures, and to explore if both extensions 
can alleviate the disadvantages of the Cox-filter method, we used actual expression values of the microarray data 
to conduct simulations. We used the first 100 gene sets in the c5 category of the Molecular Signatures Database 
and then randomly selected 4 genes – ARRB1, COPA, ECE2, and SMAD4 – to be prognostic markers. Among 
them, COPA, ECE2 and SMAD4 belong to the same gene set while ARRB1 is inside a different gene set.
Similar to the simulation setting in our previous study, we considered two extreme cases: (1) the mutually 
exclusive prognostic genes case in which AC and SCC have completely distinct sets of survival-relevant genes, 
and (2) no subtype-specific prognostic genes case in which AC and SCC share identical prognostic markers. In 
other words, for the first case, β ACs for genes 1 and 3 while β sccs for genes 2 and 4 are set to non-zero values. The 
hazard functions are specified as:
λ = λ . − λ = λ . + .exp(2 3X X ), exp(0 8X 1 7X ) (1)AC 0 ARRB1 COPA SCC 0 ECE2 SMAD4
the survival time for each patient was simulated via a Cox-exponential distribution15 according to the above haz-
ard functions, and the censoring rate was set at 30%.
For the other case, the hazard function is identical for both AC and SCC subtypes:
λ λ λ= = + . − − .X X X Xexp(2 0 8 0 9 ) (2)AC SCC ARRB ECE COPA SMAD0 1 2 4
this means that all β ACs and β sccs for genes 1–4 are expected to have non-zero coefficients. For both scenarios, we 
simulated 50 datasets and applied our proposed procedures to these replicates. The percentages of the causal genes 
being selected over the 50 replicates are summarized in Table 1 for simulation 1 and in Table 2 for simulation 2, 
Size ARRB1(%) ECE2(%) COPA(%) SMAD4(%) C-Stat (SE)% Rand (SE)%
Forward-AC 28.7 66 16 46 0 69.71(4.11) 34.68(5.56)
Forward-SCC 52.2 64 22 4 84 74.95(6.61) 28.02(2.26)
Backward-AC 49.5 0 16 40 0 66.99(3.10) 23.20(2.67)
Backward-SCC 60.4 0 44 76 54 62.65(5.55) 15.87(5.04)
Cox-filter: AC 59.2 100 4 0 0 54.09(7.09) 35.89(2.46)
Cox-filter: SCC 74.1 0 0 0 86 54.44(10.05) 26.47(2.80)
Cox-TGDR: AC 8.2 100 0 36 0 69.09(2.66) 32.13(3.33)
Cox-TGDR:SCC 3.8 100 0 4 0 53.34(7.79) 42.16(8.59)
LASSO: AC 37.8 100 94 0 2 76.00(2.20) 22.65(0.92)
LASSO: SCC 4.0 0 0 0 92 54.03(4.67) 34.05(7.75)
Table 1.  The results of simulation 1. Note: Size: the average number of selected genes over 50 replicates. 
Under each gene symbol, its frequencies of being selected over 50 replicates by different algorithms are 
presented. Forward: forward Cox-filter selection; Backward: backward Cox-filter selection.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:46164 | DOI: 10.1038/srep46164
respectively. In both tables, the C-statistics and the Rand Index at the gene level and their standard errors are 
also provided, on which the comparison between the bi-level selection  methods and other relevant algorithms, 
namely, the Cox-filter model11, the Cox-TGDR method12, and a separate LASSO16 for each subtype, was made.
In both simulations, the forward Cox-filter was superior to the backward Cox-filter in terms of the frequen-
cies of identifying the true causal genes and the sizes of the final models. Compared with the original Cox-filter 
method, which selects genes simply based on individual effects, both the forward Cox-filter method and the 
backward Cox-filter method are more likely to select those genes with small individual effects but significant 
coordinated effects together with other genes in the same gene set, i.e., COPA, ECE2, and SMAD2. Nevertheless, 
as a filter method to select genes, the model parsimony (i.e., the number of genes in the resulting prognostic gene 
signature) of these two proposed methods remains unsatisfactory.
As a reference, the percentages of these four causal genes being selected under a random guess model by both 
forward Cox-filter  and backward Cox-filter are presented in Table 3. Under the null model, almost all percentages 
of these genes being selected are zeros, suggesting the high frequencies obtained by both bi-level selection  methods 
are impossible to occur by chance alone.
Overall, the forward Cox-filter method has the best performance when the C-statistics and the Rand Index are 
considered together. The backward Cox-filter method shows no such an overall superiority. For instance, in the 
first simulation the backward Cox-filter method has the lowest Rand index (15.87%) among these 5 algorithms 
but a very large standard error (5.04%) for the SCC subtype.
Real World Data. In this application, we first trained on the NSCLC microarray data using both proposed 
methods and validated the predictive performance of the resulting gene signatures using the RNA-seq data as a test 
set. Then we reversed the order of the training set and the test set. Lastly, we applied three relevant methods—the 
Cox-filter method and the Cox-TGDR method proposed by us11,12 to test the existence of subtype-specific prog-
nostic genes, and LASSO for survival analysis17 – to the NSCLC microarray data and compared both proposed 
bi-level selection  methods and the three relevant methods. The performance statistics, i.e., the C-statistics calcu-
lated by applying the prognostic signatures on the test set and the Rand Index at the gene and gene set levels using 
10-fold cross-validations, and their standard errors obtained using bootstrapped samples are presented in Table 4.
The forward Cox-filter method outperformed the three other relevant feature selection methods and the back-
ward Cox-filter method. Of note, a non-statistically different C-index value of 52.8% (standard error: 2.75%) from 
a random guess model was obtained by the backward selection method for the SCC subtype. It is consistent with 
our expectation that the performance of the backward selection method is inferior to that of the forward selection 
method and the simulation results. However, we don’t exclude the likelihood that the backward selection method 
may be optimal for some specific data types or structures.
To verify if the resulting prognostic signatures are confounded by other known variables, i.e., age, sex, and 
smoking status, a multiple Cox regression model was fitted using the risk scores estimated from the resulting 
Size ARRB1(%)
ECE2 
(%) COPA(%) SMAD4(%)
C-Stat 
(SE) %
Rand (SE) 
%
Forward-AC 85.5 100 58 88 68 75.45(4.05) 44.44(2.76)
Forward-SCC 109.5 70 56 74 90 69.29(8.52) 38.58(2.41)
Backward-AC 110.4 64 76 92 66 72.39(4.04) 28.11(4.53)
Backward-SCC 142.3 54 56 84 86 70.62(7.28) 37.98(7.64)
Cox-filter: AC 78.9 100 20 0 74 72.31(2.38) 50.50(6.49)
Cox-filter: SCC 145.3 40 44 10 94 64.13(4.55) 21.32(8.11)
Cox-TGDR: AC 5.5 100 38 0 46 61.57(3.09) 35.03(5.43)
Cox-TGDR:SCC 8.7 98 64 22 90 54.16(4.61) 38.35(6.22)
LASSO: AC 28.7 98 72 48 98 81.27(2.10) 25.48(2.06)
LASSO: SCC 4.9 2 8 4 28 56.29(4.87) 21.35(1.27)
Table 2.  The results of simulation 2. Note: Size: the average number of selected genes over 50 replicates. 
Under each gene symbol, its frequencies of being selected over 50 replicates by different algorithms are 
presented. Forward: forward Cox-filter selection; Backward: backward Cox-filter selection. C-Stat (SE): the 
mean of C-statistics over the replicates (its corresponding standard error).
Size ARRB1(%) ECE2(%) COPA(%) SMAD4(%)
Forward-AC 2.46 0 0 0 0
Forward-SCC 8.64 0 0 4 0
Backward-AC 1.2 0 0 0 0
Backward-SCC 1.5 0 0 0 0
Table 3.  The frequencies for four causal genes under a random guess model. Note: Size: the average number 
of selected genes over 50 replicates. Under each gene symbol, its frequencies of being selected over 50 replicates 
by different algorithms are presented. Forward: forward Cox-filter selection; Backward: backward Cox-filter 
selection.
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prognostic signature and these clinical variables as covariates. The results are presented in Table 5. Based on the 
most significant p-values for the prognostic signatures, it is concluded that the resulting prognostic signatures 
possess adequate prognostic capacity in predicting the survival of NSCLC patients.
Moreover, as shown by the Venn-diagrams in Fig. 1, the selected gene sets and genes using the forward method 
and the backward method share no or limited overlap. This finding indicates that the focuses of the two meth-
ods might be distinct. While for the NSCLC application both methods tend to improve the pathway-level and 
gene-level stabilities, it appears that the increment in pathway-level stability for the forward Cox-filter method is 
dramatically larger than the gene-level stability. In contrast, the backward Cox-filter method does not possess this 
feature. Such a pattern has been overlooked by previous work in which researchers only illustrate when a method 
accounts for pathway knowledge, its stabilities at both gene and gene set levels may be improved.
In contrast, the overlaps between respective gene sets and genes for AC and SCC using either the forward 
method or the backward method are substantially larger, implying that there might exist more pan genes or gene 
sets for both subtypes than subtype-specific ones. Although we emphasize the importance of those subtype spe-
cific gene/gene sets, the critical role played by those pan gene/gene sets cannot be denied as well.
Conclusions
Using simulated data and a real-world application, we demonstrate that the forward Cox-filter method outper-
forms relevant algorithms under consideration as well as its backward counterpart in terms of gene-level and 
pathway-level stabilities and performance statistics. Given that there are numerous pathway analysis methods 
and feature selection algorithms, the forward Cox-filter method cannot be the “supermodel”—the optimal model 
for every expression data. Furthermore, as a bi-level selection method, the performance of the forward Cox-filter 
Method: subtype
10-fold cross-validations C Statistic
Rand_gene (SE) Rand_gs (SE) Test set (SE)
A. Using the microarray data as the training set
 Forward: AC 38.33% (1.51%) 51.92% (4.17%) 66.82% (3.52%)
 Forward: SCC 42.48% (1.13%) 69.89% (6.76%) 71.93% (4.38%)
 Backward: AC 46.08% (0.66%) 43.45% (2.27%) 58.29% (3.42%)
 Backward: SCC 46.04% (0.67%) 56.00% (2.99%) 52.80% (2.75%)
B. Using the RNA-Seq data as the training set
 Forward: AC 35.53% (0.67%) 57.38% (3.45%) 55.16% (5.98%)
 Forward: SCC 36.15% (0.58%) 65.72% (1.91%) 66.25% (6.20%)
 Backward: AC 40.89% (0.51%) 23.59% (5.21%) 57.28% (5.57%)
 Backward: SCC 39.56% (0.55%) 27.03% (4.66%) 60.93% (7.07%)
C. Comparison with other relevant algorithms by training on the microarray data
 Cox-filter: AC 25.25% (3.68%) — 60.34% (2.85%)
 Cox-filter: SCC 24.75% (3.65%) — 59.94% (2.55%)
 Cox-TGDR: AC 17.07% (3.31%) — 52.32% (5.49%)
 Cox-TGDR: SCC 18.65% (5.33%) — 48.83% (4.34%)
 Lasso: ACs 23.97% (2.06%) — 55.35% (6.78%)
 Lasso: SCCs 23.77% (3.47%) — 50.00% (7.88%)
Table 4.  Performance statistics for the NSCLC application. Note: Rand_gene: the rand index which 
evaluates the stability at the gene level; Rand_gs: the rand index which evaluates the stability at the gene set 
level; Forward: forward Cox-filter selection; Backward: backward Cox-filter selection; –: not available as the 
method only can carry out gene set-level selection. Sseparately on each subtype because the method itself does 
not account for subtype information; SE: the standard errors obtained using the bootstrapped samples. In last 
column, the C-statistics and their standard errors for different methods on the test set are listed.
Forward: AC Forward: SCC Backward: AC Backward: SCC
β (p-value) β (p-value) β (p-value) β (p-value)
Signature (risk score) 1.6(9.2× 10−7)* 1.85(0.02)* 3.01(3.4× 10−6)* 4.24(0.02)*
Female versus male − 0.27(0.39) − 0.21(0.99) − 0.23(0.46) − 0.21(0.99)
Age 0.03(0.08) 0.04(0.37) 0.03(0.11) 0.02(0.69)
Smoking vs non-
smoking 0.24(0.47) − 2.18(0.05)* 0.26(0.43) − 1.91(0.08)
Table 5.  Adjusted prognostic values of the resulting signatures in present of other clinical factors. Note:  
β : the estimated coefficient values in the multivariate Cox regression model using the prognostic signature, age, 
sex, and smoking status as covariates, representing the log hazard ratio. *p-value < 0.05, which is regarded as to 
be statistical significance.
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method relies on the quality of pathway knowledge. More specifically, these two proposed bi-level selection meth-
ods make an implicit assumption that all genes within a specific gene set shall co-function together to influence 
the phenotype of interest, which may not be true for all diseases.
We emphasize that we do not make any recommendation on the clinical utilization of the resulting prognostic 
gene signatures or gene set signatures. The primary objective of this study is to introduce the two bi-level selection 
methods. These two methods are easily implementable and readily interpretable, even for a biologist or clinician 
since it builds upon the Cox-models18 and the signed averages of expression values over a gene set or selected 
subset14. Therefore, they are easily accessible for researchers who are interested in exploring the prognostic value 
of gene expression data for specific subtypes or stages of a disease. As the first effort to address the issue of identi-
fying both subtype-specific prognostic gene sets and genes for the early-stage NSCLC patients while accounting 
for the pathway information, the proposed methods may spark interest in this research area and propel the devel-
opment of more advanced statistical methods.
Methods
Experimental Data. The RNA-Seq data for those patients at early histology stages (stages I and II) were 
downloaded from The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/). By restricting the patients to 
those at early stages and being adjuvant treatment naïve with survival information, 70 AC and 55 SCC subjects 
remained.
The microarray data used were the experiments of GSE50081 in the GEO repository. The chips in this data-
set were hybridized on the Affymetrix HGU133Plus 2.0 platform. After deleting those samples with ambiguous 
labels, 127 AC and 42 SCC patients were included in this study.
Gene Sets. Gene sets were downloaded from the Molecular Signatures Database (MSigDB)19. In this study, we 
considered only the c5 category. The current version (version 5.1) of the MSigDB c5 category includes 1554 gene 
sets annotated by the Gene Ontology (GO)20 terms.
Pre-processing Procedures. Raw data (CEL files) of the microarray data set were downloaded from the 
GEO repository. Expression values were obtained using the fRMA algorithm21, and were normalized using quan-
tile normalization. Then moderated t-tests using limma22 were carried out to identify the differentially expressed 
genes (DEGs) between SCC and AC in the microarray data set, and those non-DEGs with the false discovery rate 
(FDR) > 0.05 were filtered out. To deal with multiple probe sets matched to one specific gene, the one with the 
largest fold change was retained.
For the RNA-seq data, Counts-per-million (CPM) values were calculated and log2 transformed by the Voom 
function23 in R limma package22. The downstream analysis was conducted upon the 2569 genes inside microarray 
data, RNA-seq data, and the annotated gene sets.
Statistical Methods. Cox-filter for subtype-specific prognosis. The Cox-filter method proposed by us11 is 
used to identify genes informative of survival rate for AC/SCC histology subtypes. In this method, a Cox model is 
fitted on each gene, and the hazard function of patient i for gene g (g = 1,… ,p) at time point t is given by,
λ λ β β β= = + + = ×( )t I j SCC X I j SCC X( ) (t)exp ( ) ( ) (3)ijg g g g ijg g ijg0 1 2 3
Figure 1. Venn diagrams showing the overlaps between the selected gene/gene sets for AC and SCC. (A) 
At the gene level: F_AC: the selected genes by the forward method for AC; F_SCC: the selected genes by the 
forward method for SCC; B_AC: the selected genes by the backward method for AC; B_SCC: the selected genes 
by the backward method for SCC; (B) At the gene set level: sccf: the selected gene sets by the forward method 
for SCC; acf: the selected gene sets by the forward method for AC; sccb: the selected gene sets by the backward 
method for SCC; acb: the selected gene sets by the backward method for AC.
www.nature.com/scientificreports/
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here, Xij = (Xij1,… ,Xijp)T represent expression values for the p genes under consideration and λ 0g(t) is an unknown 
baseline hazard function at time point t. I(j= SCC) is an indicator, taking the value of 1 if the histology subtype 
j of patient i is SCC. Otherwise, its value is 0 if the histology subtype of this patient is AC. Both β 2g and β 3g are 
the parameters of interest, with β 2g representing the change in log hazard rate associated with 1-unit increase in 
the actual expression value of gene g among AC, and β 3g representing the additional change in log hazard rate 
associated with the SCC subtype. The values of β ACg, i.e., β 2g, and β SCCg, i.e., β 2g + β 3g, determine if subtype-specific 
prognostic genes do exist. For example, β ACg≠ 0 but β SCCg = 0 corresponds to an AC-specific gene and β SCCg≠ 0 but 
β ACg  =0 corresponds to an SCC-specific gene. In practice, we may also be interested in the scenario of both β ACg 
and β SCCg having different non-zero values.
Sign average. After fitting the Cox-filter model for each gene and obtaining estimated β ACg and β SCCg for each 
gene, we take the membership of genes into consideration and then summarize a patient’s risk profile as the sign 
average of his/her expression values over all genes/selected genes inside each specific gene set.
Specifically for each subtype, all genes/selected genes inside this gene set are classified into two groups accord-
ing to the signs of their estimated effects in the above equation — the hazardous group H and the preventive 
group P. In the first group, genes with increased expression that are associated with higher hazard are included. 
In contrast, genes for which an increment in expression reduces hazard are classified into the second group. Since 
one gene may be hazardous in one subtype while preventive in the other, we introduce two sets of notations for 
the AC and SCC patients, i.e., HAC and PAC for AC patients, and HSCC and PSCC for SCC patients.
Then the sign average Zijk for patient i of subtype j (either AC or SCC) in gene set k is calculated as
∑ ∑=



−



+
∈ ∈
Z X X H P/( )
(4)
ijk
l H
il
l P
il k
j
k
j
k
j
k
j
here Hk
j  is the number of genes inside gene set Hk
j. and Xil represents the gene expression value of gene l (l 
includes all genes belong to one specific gene set) for patient i. By taking the difference between the sum of expres-
sion values of all genes inside the hazardous group H and that of all genes inside the preventive group P and then 
dividing by the total number of genes/selected genes, Zijk is essentially the signed average of expression values 
over genes under consideration inside gene set k.
Extensions to the Cox-filter model for bi-selection. In order to implement bi-level selection with the Cox model 
in Eq. 3, we apply it twice in a either forward or backward way. Correspondingly, we refer them as the forward 
Cox-filter method and the backward Cox-filter method.
Forward Cox-filter. In the forward Cox-filter extension, the risk profiles for patient i are first calculated over all 
genes inside the specific gene set k, denoted as Zijk. Here, Zij = (Zij1,… ,ZijK)T is a K-length vector representing the 
gene set level risk profiles for patient i over K gene sets under consideration.
Replacing genes by gene sets, then the Cox-filter model is fitted again. For one specific gene set k (k = 1,2,… ,K, 
here K is the number of gene sets under consideration), the Cox-filter model may be expressed as,
λ λ β β β= = + + = ×( )t t I j SCC Z I j SCC Z( ) ( )exp ( ) ( ) (5)ijk k k k ijk k ijk0 1 2 3
where Zijk is the sign average obtained in Eq.4, representing the expression level of gene set k for patient i. After 
filtering out those insignificant gene sets for whose adjusted p-values (using the procedure) are larger than a 
pre-determined cut-off, the significant levels of genes inside the identified gene sets are determined on the basis 
of the adjusted p-values of the Cox-filter models in Eq. 3.
Backward Cox-filter. Taking the reversed selection orders, the backward Cox-filter extension first selects can-
didate genes based on the adjusted p-values of the Cox-filter models in Eq. 3 and then calculates the risk profiles 
over those selected genes for each gene set. Lastly, the significant levels of gene sets are determined using the 
adjusted p-values of the Cox models in Eq. 5. Correspondingly, the final selected genes are those involved in the 
first step and also contained inside those significant gene sets.
In both procedures, the adjusted p-values in Eq. 3 and Eq. 5 may be treated as tuning parameters. Over a 
grid of values, i.e., 0.01, 0.05, 0.1, 0.15 and 0.2, their optimal values are decided using 10-fold cross-validations. 
Figure 2 provides graphical elucidation of both the forward Cox-filter method and the backward Cox-filter 
method.
Statistical Metrics. We use the censoring-adjusted C-statistic24 over the follow-up period (0,τ ) to evaluate 
the performance of a resulting prognostic gene signature, where τ is a pre-specified time point. The C-statistic is 
defined as,
β τ= > < <τ ( )C P g X g X T T T( ) ( ) ( ) , (6)i j i j i
where g(Xi) is the risk score for subject i with predictor vector Xi and Ti is the survival time of patient i.
The C-statistic can be interpreted as the probability of concordance between the predicted and observed sur-
vival times over all pairs of observations over the follow-up period (0,τ ). Its asymptotic distribution is presented 
in the Appendix of the original paper24. Empirically, even though a value of 0.5 for the C-statistics corresponds 
to the random guess model, a prognostic signature with the C-statistic of relatively moderate values, i.e., between 
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0.6–0.7 is regarded to have satisfactory predictive performance25. The calculation of the C-statistic is implemented 
using the R survAUC package.
In addition, the Rand index is calculated to evaluate the stability or robustness of the resulting signatures. 
With k runs (e.g., the runs in an k-fold cross-validation or the applications of the method to k different data sets) 
of an algorithm, k lists of genes are obtained, i.e., gs1, gs2, … gsk. Then a Rand index is defined as
∑ ∑
∩
∪
=
− =
−
= +
Rand
k k
gs gs
gs gs
2
( 1)
( , )
( , ) (7)i
k
j i
k i j
i j1
1
1
where ∩ represents the intersection between two gene lists, ∪ represents the union between the gene lists gsi and 
gsj, and | | stands for the size of the corresponding set. The Rand index represents the agreement among the result-
ing signatures trained from different data sets.
With the gene lists being replaced by the pathway lists, the stability of resulting gene sets is evaluated using 
the Rand index.
Statistical Language and Packages. All statistical analysis was carried out in the R language version 3.2 
(www.r-project.org).
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